Table 3 Phenotypic features of patient-derived effector cells after 21 days in culture.
Pt # | CD3+CD8+ (T cells) | CD3+CD16+CD56+ (CIK cells) | CD3-CD16+CD56+ (NK cells) |
|---|---|---|---|
1 | 78% | 57.64% | 0.5% |
2 | 81.5% | 40.5% | 1.2% |
3 | 79.8% | 36.3% | 12.2% |
4 | 71.2% | 51.2% | 3.1% |
Pt # | CD3+CD8+ (T cells) | CD3+CD16+CD56+ (CIK cells) | CD3-CD16+CD56+ (NK cells) |
|---|---|---|---|
1 | 78% | 57.64% | 0.5% |
2 | 81.5% | 40.5% | 1.2% |
3 | 79.8% | 36.3% | 12.2% |
4 | 71.2% | 51.2% | 3.1% |